Your search for Warfarin returned 18 results

The new findings were based on data from a pooled analysis of two large U.S. commercial health insurance databases.

At ACC.13, the American College of Cardiology’s 62nd Annual Scientific Session, leading cardiologists presented that the use of dabigatran following ablation for atrial fibrillation resulted in no major post-procedural complications.

The community-based, Phase 3b randomized, open-label, multicenter UPFRONT trial presented at the 53rd American Society of Hematology Annual Meeting and Exposition has found that three bortezomib-based regimens followed by weekly bortezomib maintenance therapy produced similar overall response rates (ORR), progression-free survival (PFS), and 1-year overall survival (OS) in elderly, newly diagnosed, transplant-ineligible multiple myeloma (MM) patients.

Dabigatran 150mg was superior to warfarin and dabigatran 110mg was noninferior to warfarin for preventing stroke in patients with atrial fibrillation (AF) regardless of CHA2DS2-VASc scores, as shown by the results of a subgroup analysis of the RE-LY trial presented today at ACC.11, the American College of Cardiology’s 60th Annual Scientific Session.

A subgroup analysis from the RE-LY trial has demonstrated that in patients with atrial fibrillation (AF), twice-daily dabigatran etexilate has better efficacy and lower rates of major bleeding when compared with warfarin, as reported at ACC.11, the American College of Cardiology’s 60th Annual Scientific Session.

A prospective phase 2 study of the low-molecular-weight heparin (LMWH) tinzaparin for initial treatment and secondary prophylaxis of venous thromboembolism (VTE) associated with cancer treatment found the agent to be safe and efficacious, with the recurrent VTE event rate comparing favorably with that reported for another LMWH, dalteparin according to a study presented at the 52nd American Society of Hematology Meeting and Exposition.

Patients with newly diagnosed or previously treated multiple myeloma (MM) who receive thalidomide (T)- or lenalidomide (L)-based regimens are at high risk of venous thromboembolism (VTE), and it is uncertain whether thromboprophylaxis provides a clear benefit, especially in those who receive L-based therapy or have previously treated disease, according to results of a systematic review and meta-analysis that were shown at the 52nd American Society of Hematology Meeting and Exposition.

Novel oral anticoagulants, that do not require the laboratory monitoring associated with warfarin therapy, may alter the landscape of venous thromboembolism treatment and stroke prevention in atrial fibrillation, according to a study presented at the 52nd American Society of Hematology Meeting and Exposition.